Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies.
about
Update on the emerging role of telavancin in hospital-acquired infectionsIn Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure.Evaluation of Pharmacodynamic Interactions Between Telavancin and Aztreonam or Piperacillin/Tazobactam Against Pseudomonas aeruginosa, Escherichia coli and Methicillin-Resistant Staphylococcus aureus.Efficacy of telavancin, a lipoglycopeptide antibiotic, in experimental models of Gram-positive infection.A review of telavancin activity in in vitro biofilms and animal models of biofilm-associated infections.Telavancin: the long and winding road from discovery to food and drug administration approvals and future directions.Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus.Telavancin Is Active against Experimental Aortic Valve Endocarditis Caused by Daptomycin- and Methicillin-Resistant Staphylococcus aureus Strains.Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical Isolates.Evaluation of Antibiotics Active against Methicillin-Resistant Staphylococcus aureus Based on Activity in an Established BiofilmComparative efficacy of telavancin and daptomycin in experimental endocarditis due to multi-clonotype MRSA strains.A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically.Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011-2013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin.Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United StatesBaseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method.In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census Divisions.Pharmacokinetics of Telavancin at Fixed Doses in Normal Body Weight and Obese (Classes I, II, and III) Adult Subjects.Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides.In Vitro Activity of the Novel Lactone Ketolide Nafithromycin (WCK 4873) against Contemporary Clinical Bacteria from a Global Surveillance Program.Telavancin for the treatment of methicillin-resistant Staphylococcus aureus infections.Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients
P2860
Q28083522-0912C6B4-1CB8-4444-8B8D-D2FF106ECDDEQ36439072-27CB54A2-2A22-43DE-A0EF-692115C04A2FQ37250189-0E0189EA-B8D8-477B-993F-8D1EA260704AQ38266421-7C65FF86-F52D-4A00-9E34-FAEF6744EB34Q38530316-0AB3CA5F-1C51-4E38-A49A-986AFA20CE5BQ38575714-F87DDBF7-B9A0-4E09-9501-D44BB9C79037Q38833633-D13E73A1-5810-4088-8AB8-B2E5F96849A9Q40441728-32DFFED6-7EEF-41B6-9F01-91C90B2BF482Q40513210-723A3570-D66A-450C-915C-558F48906D49Q40617957-666774FB-16C9-467E-80E8-4A8FCF162D73Q40633251-6BE142E8-79C4-477C-BEF1-93A247A78AD9Q40993969-92256314-D7D9-4D4F-BC8A-B5D2D70FF68EQ41028154-5338B46F-5A61-4AC9-8F65-6849E8558AF2Q41172790-4D39B7F3-552F-402D-B4A7-0F5AF08164D5Q41561992-1BA7A98F-13EB-4D24-BD35-30A526D26CCCQ41687426-74492E68-56CB-48C8-AA53-CA4A3148374AQ42680740-E9F2761E-8BB8-4BCD-B545-2291D7211BB9Q47172132-75411132-F464-4EA7-9B70-1DD6DD9E969BQ50053159-D0409A3F-7C90-4B21-A57A-1530ADF91FD8Q53723800-62E9D48F-A82C-4C00-AE7C-0EFCF1C35748Q53823457-6F469063-5F85-4C56-AF60-F8DA74BE83D1Q58700574-2B9E20F9-600B-4CA1-A823-8E1D601BB4C8
P2860
Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Revised reference broth microd ...... h other testing methodologies.
@en
Revised reference broth microd ...... h other testing methodologies.
@nl
type
label
Revised reference broth microd ...... h other testing methodologies.
@en
Revised reference broth microd ...... h other testing methodologies.
@nl
prefLabel
Revised reference broth microd ...... h other testing methodologies.
@en
Revised reference broth microd ...... h other testing methodologies.
@nl
P2093
P2860
P356
P1476
Revised reference broth microd ...... h other testing methodologies.
@en
P2093
David J Farrell
Paul R Rhomberg
Rodrigo E Mendes
Ronald N Jones
P2860
P304
P356
10.1128/AAC.03172-14
P407
P577
2014-07-14T00:00:00Z